Clinical trial shows 15-day Paxlovid regimen safe but adds no clear benefit for long COVID

In a clinical trial conducted by Stanford Medicine investigators and their colleagues, a 15-day course of Paxlovid—an antiviral drug combination targeting SARS-CoV-2, the virus that causes COVID-19—proved safe as an extended-duration treatment but didn’t lessen select symptoms of the syndrome known as long COVID: the persistence, or reappearance, of COVID-related symptoms three months or more after an initial COVID-19 infection.

Facebook Comments